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Abstract
Spasticity and dystonia are two neurological conditions with a broad range of 
clinical manifestations that can emerge at any age. Although the spasticity and 
dystonia symptoms are caused by different pathophysiological mechanisms, both 
of them may cause functional impairment that contributes to a poor quality of life. 
Spasticity is characterised by a velocity-dependent increase in tonic stretch reflexes 
with exaggerated tendon jerks, resulting from hyperexcitability of the stretch 
reflex. It mostly occurs in disorders of the central nervous system (CNS) affecting 
the upper motor neurons, such as multiple sclerosis, amyotrophic lateral sclerosis, 
cerebrovascular diseases, cerebral palsy, traumatic brain injury, stroke, and spinal 
cord injury. Therapeutic options may combine, in various proportions, physical 
therapy, occupational therapy, self-rehabilitation, the use of orthoses and assis-
tive devices, drug treatment, orthopaedic surgery, and neurosurgery. Dystonia is 
defined as a syndrome of involuntary movement that manifests as excessive muscle 
contractions that frequently cause twisting and repetitive movements or abnormal 
postures. It is often intensified or exacerbated by physical activity, and symptoms 
may progress into adjacent muscles. Dystonia has many different manifestations 
and causes, and many different treatment options are available. These options 
include physical and occupational therapy, oral medications, intramuscular injec-
tion of botulinum toxins, and neurosurgical interventions.
Keywords: spasticity, dystonia, treatments, oral drugs, rehabilitation
1. Introduction
According to Lance and colleagues, spasticity is a “…motor disorder charac-
terised by a velocity dependent increase in the tonic stretch reflex with exagger-
ated tendon jerks, resulting from hyperexcitability of the stretch reflex, as one 
component of the upper motor neuron syndrome…” [1]. Over time, the interest of 
clinicians on spasticity has increased more and more, topics ranging from patho-
physiology to clinical relevance and treatment options [2–8].
However, in everyday management of patients’ spasticity symptoms, much 
more complex situation would be there, full of clinical problems. In fact, other 
positive and/or negative signs may be observed together with increased muscle tone 
and deep tendon reflexes. Abnormal cutaneous reflexes, spasms, co-contraction, 
Babinski reflex, and also dystonia, are described as positive phenomena, and weak-
ness, fatigability, and reduced dexterity are considered negative ones. In clinical 
practice each problem that we have to treat may have different pathophysiological 
explanations [9]. A central nervous system lesion determines the upper motor 
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neuron syndrome, induced by an interruption of descending pathways, which con-
nect the highest centres to the spinal cord. Alternatively, reactivity of spinal cord 
circuits may be modified by a direct damage, through a different way to elaborate 
the input from peripheral afferents. It is important to differentiate immediate to 
delayed consequences of damage to the highest centres in the CNS. The delayed 
consequences lead to a rearrangement of reactivity in spinal cord circuits, in which 
it is considered a basis of spasticity. Moreover, spasticity may itself be modified by 
the consequences of paresis and immobilisation, i.e. development of contractures. 
Several pathophysiological mechanisms may explain the development of spasticity 
due to CNS lesions. These mainly include defective inhibition, such as postsynaptic 
inhibition of alpha motor neurons or presynaptic inhibition of 1a afferents. There is 
also a defective excitation of inhibitory interneurons underlying reciprocal inhibi-
tion, autogenetic inhibition, or recurrent inhibition [10].
Dystonia is defined as a neurological disorder characterised by sustained or 
intermittent muscle contractions, determining unusual movements and postures 
or both. Typically dystonic movements are patterned and twisting and may be 
tremulous. Often, dystonic movements may be started by voluntary action, worsen-
ing with typically an overflow muscle activation (Consensus 2013) [11]. Dystonia 
classification is based on clinical characteristics and aetiology. Indeed, except for 
hereditary forms, dystonic syndromes may be caused by birth-related or other 
physical trauma, infection, and poisoning or due to pharmacological treatments, 
particularly neuroleptics. The clinical characteristics include age at onset, temporal 
pattern, body distribution, and coexistence of other movement disorders. The 
etiologic characteristics are the presence or absence of nervous system pathology 
and the pattern of inheritance [11].
Focal dystonia is a neurologic movement disorder, due to an incorrect sensorimo-
tor modulation, determining involuntary, excessive muscle contractions. Writer’s 
cramp is a specific type of focal dystonia that affects the fingers, hand, or forearm. 
Writer’s cramp is a task-specific dystonia, characterised by hands twisting into odd 
postures. A specific task induces this sign. Other skilled task-specific movements may 
induce focal hand dystonia, such as playing a musical instrument, typing, or sewing. 
Writer’s cramp is known also as musician’s cramp, focal hand dystonia, arm dystonia, 
finger dystonia, task-specific dystonia, and occupational cramp or dystonia.
Task-specific dystonia like writer’s cramp may appear in anyone. It usually 
appears between 30 and 50 years of age. Task-specific dystonia, particularly musi-
cian’s cramp, is more common in men.
Two types of writer’s cramp could be described:
1. Simple writer’s cramp, which appears only during writing. The abnormal 
postures spring up soon after you pick up a pen. So, it only affects the ability to 
write.
2. Dystonic writer’s cramp appears not only during writing but also during other 
activities with your hands, like shaving, dressing, or applying makeup.
Probably, repetitive movements determine a remapping of the brain’s senso-
rimotor areas. Bad posture of the hands while holding a pen or pencil associated 
with overuse seems to cause simple writer’s cramp. Dystonic writer’s cramp is less 
common than simple ones and may represent a symptom of generalised dystonia. 
In this case, the involuntary movements can appear also during other non-writing 
tasks, such as using a fork or handwashing. Rarely, writer’s cramp could be the early 
onset of a generalised dystonia, which is associated with the DYT1 gene [12].
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1.1 Pathophysiology of spasticity and dystonia syndromes
Typically, spasticity is considered as a specific “pyramidal” sign; neverthe-
less, selective lesions of the primary motor cortex or corticospinal tract often 
induce hypotonia, deficit, or weakness in distal movements, without inducing 
spasticity [4]. Only the involvement of non-primary motor areas (premotor and 
supplementary areas) and the corticoreticulospinal fibres together with cortical 
lesions may induce spasticity. Corticoreticulospinal fibres sends through the 
dorsolateral reticulospinal tract descending just anteriorly to the corticospinal 
tract, a massive bilateral inhibitory projection to spinal motor neurons, which 
are located in the lateral funiculus of the spinal cord. So the fact that a selective 
lesion of the anterior limb or the genu of the internal capsula predominantly 
induces spasticity without an evident motor deficit and vice versa can be 
explained by the different courses of corticoreticular and corticospinal fibres 
in the internal capsula. Hence, a lesion involving the corticoreticulospinal 
fibres will lead to a decreased inhibition (or to an increased facilitation) of the 
spinal cord and ultimately to spasticity [13, 14]. Three fundamental phenomena 
occur after a lesion to the central motor pathways assigned to motor command 
execution:
1. Paresis: the quantitative lack of command directed to agonist muscles when at-
tempting to generate force or movement.
2. Soft tissue contracture and contractile muscle property changes: shortened posi-
tion induced by immobilisation due to paresis, causing soft tissue and muscle 
alterations. [13].
3. Muscle overactivity: as a consequence of corticospinal pathway lesion, which 
causes loss of motor command, brainstem descending pathways are activated. 
Most of these brainstem descending pathways tend to be constantly active, as 
a consequence a constant muscle activity is maintained. Releasing of growth 
factors locally is induced in the spinal cord level by the lack of regular descend-
ing excitation to the lower motor neurons. So these phenomena induce local 
sprouting from neighbouring interneurons, creating perfect conditions in 
order to synthetise new abnormal synapse network, leading to the creation of 
new abnormal reflex pathways [8, 9].
1.2 Spasticity
Among these changes, which gradually develop, spasticity represents the 
principal sign detectable. A simple definition of spasticity is an increase in velocity-
dependent stretch reflexes [9, 10] which can be evoked at rest by muscle stretch or 
tendon taps.
Principal key points:
• A tonic stretch reflex.
• Mediated by type 1a fibre nerve, predominantly in the muscle spindle. Passive 
muscle stretch induces exciting of muscle spindle, which sends sensory input 
back to the spinal cord through monosynaptic way principally but also oligo- 
and polysynaptic reflexes, which at the end induce an efferent impulse to the 
muscle, causing contraction.
Neurostimulation and Neuromodulation in Contemporary Therapeutic Practice
4
• Velocity-dependent.
• Length-dependent.
1.3 Spastic dystonia
The term “spastic dystonia” was coined by Denny-Brown in 1966 to define 
tonic-chronic muscle activity that is present in a spasticity pattern, during rest [15]. 
Thus, spastic dystonia could be described as a spontaneous overactivity at rest, not 
induced by a primary triggering factor [14–16]. It is easy to recognise it in patients 
with spastic paresis, as spastic dystonia causes specific bad postures in joints and 
body. For example, in the upper limb, the shoulder can stay internally rotated 
and adducted with a flexed and pronated elbow and flexed wrist and fingers. 
Equinovarus deformity represents a specific spastic dystonia in the lower limb, and 
it is characterised by plantar flexors and/or toe flexors, which may be painful and 
disabling during walking.
1.4 Spastic co-contraction
Spastic co-contraction is defined as an “unwanted, excessive, level of antagonis-
tic muscle activity during voluntary command on an agonist muscle, which is aggra-
vated by tonic stretch in the co-contracting muscle” [13]. Spastic co-contraction in 
spasticity pattern is a descending phenomenon, most probably due to misdirection 
of the supraspinal drive. It may be caused by loss of reciprocal inhibition during 
voluntary command [9, 10]. So, voluntary command of an agonist muscle is the 
first step, which induces spastic co-contraction. In patients with good or fairly 
good motor control, spastic co-contraction is certainly the most disabling form of 
muscle overactivity, because it obstacles muscle physiological muscle voluntary 
recruitment.
1.5 Clinical evaluation
1.5.1 Passive range of motion
For each movement evaluated, the corresponding muscles and joints are 
stretched at a very slow speed, in order to keep below the threshold for eliciting a 
stretch reflex. The angle at which soft tissue offers a maximum resistance is defined 
as the passive range of motion for that joint [17].
1.5.2 Angle of catch or clonus and spasticity grade
For each movement evaluated, the clinician should stretch the correspond-
ing muscles and joints as fast as possible for the examiner. The spasticity grade is 
determined by the joint angle at which catch or clonus appears, according to Tardieu 
scale [18].
1.5.3 Active range of motion
For each passive movement evaluated at first, the clinician asks the patient to 
carry out an active movement at maximal range, until the active movement pro-
duced by the agonist muscles is contrasted by the passive resistance together with 
the spastic co-contraction of antagonist ones. This angle measure is the effective 
active range of motion [18].
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1.5.4 Outcome measure
Tardieu score is a scale realised to measure spasticity that evaluates resistance to 
passive movement at both slow and fast speed. Individuals are evaluated both in in 
sit and supine position. There are two types of measures:
1. Quality of muscle reaction.
2. Angle of muscle reaction.
The quality of muscle reaction is scored as follows (range 0–4):
0. No resistance throughout the course of the passive movement.
1. Slight resistance throughout the course of the passive movement, followed by 
release.
2. Clear catch at precise angle, interrupting the passive movement, followed by 
release.
3. Fatigable clonus (<10 seconds when maintaining pressure) occurring at precise 
angle.
4. Infatigable clonus (>10 seconds when maintaining pressure) occurring at 
precise angle.
In order to consider joint angle, speed movement has to be defined:
• V1 is slow as possible.
• V2 speed of limb falling under gravity.
• V3 moving as fast as possible.
Regarding the joint angle, modified Tardieu describes:
• R1 as the angle of muscle reaction.
• R2 as the full PROM.
The angle of full ROM (R2) is defined at a very slow speed (V1). The angle of 
muscle reaction (R1) is detected when a catch or clonus appears during a quick 
stretch (V3) [19].
Ashworth scale, original version (1964), is a test which quantifies resistance 
to passive movement, with respect to a joint and with varying degrees of velocity. 
Scores range from 0 to 4:
0. No increase in tone.
1. Slight increase in tone giving a catch when the limb was moved in flexion or 
extension.
2. More marked increase in tone but limb easily flexed.
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3. Considerable increase in tone, passive movement difficult.
4. Limb rigid, sometimes fixed in flexion or extension.
The modified Ashworth scale (Bohannon & Smith, 1987) is similar to the 
original one, except for a 1+ scoring category to indicate resistance through less than 
half of the movement [20].
2. Treatment options of spasticity
2.1 Indications for treatment
It’s demonstrated that burden of care is higher in neurological patients who 
developed spasticity than that of those without it, in particular regarding treat-
ment costs, quality of life, caregiver burden, and the effects of comorbidities 
[21]. The treatment of muscle overactivity may be considered when the condition 
is disabling. Muscle overactivity usually impairs motor command, so this itself 
justifies the treatment. Moreover, independently from the aetiological context, it 
contributes to impair patient’s function [22]. Nevertheless, not all patients with 
muscle overactivity need a specific treatment. Treatment in spasticity should be 
carried out only after rigorous clinical analysis, in order to determine the severity of 
functional impairment. A multidisciplinary approach is necessary in order to obtain 
this specific assessment, being different according to patient’s clinical condition; it 
may include variably physician, physical therapist, occupational therapist, nurse, 
and/or caregiver [22]. In order to obtain an individual, task-oriented therapeutic 
strategy, it is necessary to analyse a list of personal measurable objectives, which 
may be different for each patient. The clinical follow-up is required in order to show 
the benefits as well as adverse events. Muscle spasticity, which usually is responsive 
to drug treatment, is not the only motor impairment in spastic paresis. It is neces-
sary also that physiotherapy is associated to drug treatment, in order to obtain 
maximum gain in paresis. For example, stretch programmes can be used to treat 
soft tissue shortening. Therefore, before treatment, the following three questions 
must be answered:
• Is muscle overactivity handicap an activity of daily living? Only after a detailed 
analysis of the functional impairment induced by spasticity, it is possible to 
carry out an appropriate treatment, which could be really effective to improve 
patient’s quality of life.
• Is disability caused by muscle spasticity, or is it only a comorbidity? In the lat-
ter case, which components are involved? It is important to specify the quality 
of motor control and weakness. If motor impairment is induced or worsened 
by muscle overactivity, its treatment is to be considered mandatory, in order to 
be helpful to the patient [23].
• Does muscle overactivity involve one specific muscle group, or does it spread to 
other? The correct therapeutic approach depends on the answer.
Pharmacological interventions for spasticity can be divided into two groups: 
those that act systemically and those that act locally [24] with the locally act-
ing treatments tending to be more invasive, systemically acting drugs used as 
a first step [24]. If a systematic approach, which includes baclofen, tizanidine, 
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or dantrolene, is not successful, local treatment is allowed [25], such as muscle 
botulinum toxin (BTX) injection or peripheral neurolytic blockade with alcohol 
or phenol [26]. Surgery is to be considered as the final treatment option; however, 
it is rarely used. If the principal aim is to inhibit neurotransmitter activity at one 
or more sites within the central nervous system, a systemic approach with specific 
drugs is to be evaluated. Targeted therapy could regard pre- or postsynaptic sites 
in spinal interneurons (at varying levels of the upper motor neuron pathway), 
alpha motor neurons, as well as primary sensory afferent neurons. So, the central 
nervous system is influenced by inhibitory effects of the neurotransmitters [27]. 
Oral administration needs high drug dose in order to cross the blood–brain barrier; 
therefore, side effects like dizziness could occur. In order to reduce the probability 
for these negative effects, it is possible to introduce some drugs directly into the 
cerebrospinal fluid, for example, by an intrathecal pump. For drugs used peripher-
ally via injection directly to the nerve or muscle, systemic side effects are fewer.
2.2 Physical therapy
Physiotherapy is the basic treatment for all patients with spasticity [28, 29]. 
It may help limit muscle contractures and reduce overactivity for a short period. 
Physiotherapy together with drug treatment is fundamental to obtain the best func-
tional gain, in order to help patients adapt to changes. In all cases, physiotherapy 
must be considered as complementary to drugs and surgery. In fact, stretching is 
considered an import goal in a physiotherapy session, as largely demonstrated [30]. 
Functional electrical stimulation allows spasticity reduction in antagonists of the 
stimulated muscles. An interesting use of electrical stimulation is the stimulation 
of hand and finger extensors during prehension training and mixing of overactive 
flexor inhibition with extensor activation [31]. Finally, it is important to educate 
patient in self-rehabilitation sessions comprehensive of stretching postures and 
active exercises, eventually assisted by caregivers and/or orthoses.
2.3 Oral drugs
Pharmacologic approaches emphasise oral drugs, neuromuscular blocks, and 
intrathecal agents. Usually, antispastic therapy is initiated with oral drugs, even 
though adverse side effects are frequently reported as a systematic effect [32]. 
Treatment decisions on specific pharmacologic approach are influenced by chronic-
ity, severity, and localisation of spasticity. It was demonstrated that pharmacologic 
treatments are most effective if used early, in order to avoid muscle shortening 
and contracture development [33]. However, the time to treat is the first problem 
to resolve, in particular for drugs. Correctly, spasticity treatment is recommended 
when it induces a significant functional impairment, in particular regarding daily 
living activities, or clinical disability such as bad posture, motor capacity, or nurs-
ing. When spasticity is diffusely distributed above all in lower limbs, often observed 
as a consequence of spinal lesions, its treatment is firstly indicated, than in cerebral 
lesions.
The general goal of medical treatment is to decrease spinal reflex excitability by 
reducing the release of excitatory neurotransmitters or by potentiating the activity 
of inhibitory circuits. In clinical practice it is important to differentiate objectives 
in giving spasticity drugs. The technical objectives are focused to induce tone 
reduction, in order to increase range of motion or ameliorating joint position and 
promote rehabilitative procedures. Nevertheless, we also have functional therapeu-
tic objectives regarding gait improvement, daily living activity, self-care, and spasm 
and pain reduction. When we evaluate the real effectiveness of different drug 
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approaches, it is important to differentiate these therapeutic objectives. In order 
to achieve these therapeutic goals, most of the drugs currently used in spasticity 
influence the activity of the CNS neurotransmitters. Inhibitory neurotransmit-
ters (GABA or glycine), as well as excitatory neurotransmitters (glutamate or the 
monoamines), are the main target. Diazepam, baclofen, tizanidine, and dantrolene 
represent the principal drugs more frequently used.
2.3.1 Diazepam
Diazepam, probably the first and oldest drug used in treating spasticity [34, 35], 
is a GABA-A receptor agonist. Its binding, to GABA-A receptors diffused in the 
brainstem and spinal cord, acts in increasing presynaptic inhibition. Consequently, 
reduction in the resistance to stretch is the principal clinical effect, showing an 
objectively increasing range of motion. Other clinical effects are also a reduction 
of deep tendon stretch reflexes and painful spasms [36]. Nevertheless, significant 
side effects are to be considered. The depressant effect of the drug on the CNS is the 
principal side effect, causing an influence on cognitive-level, consciousness status, 
leading to sedation, drowsiness, and attention or memory impairment. The same 
physiological mechanism explains weakness and motor discoordination caused 
by diazepam. Tolerance or dependency phenomena are often observed [37, 38]. 
Spasticity caused by spinal cord lesion, above all incomplete ones like in patients 
with multiple sclerosis (MS), is the principal indication to use diazepam, since the 
drug binding is mainly in the brainstem. Less literature are available for the use of 
diazepam in spasticity caused by cerebral accident, such as traumatic brain injuries, 
cerebral palsy, and stroke. In literature, a double-blind protocol is available showing 
the antispastic efficacy of diazepam, only in spinal cord lesions [39]. However, a 
possible strength and gait deterioration was also shown consistently in placebo-
controlled studies.
2.3.2 Gabapentin
Gabapentin is approved as an antiepileptic drug. It is indicated also for posther-
petic neuralgia treatment and as add-on therapy in partial seizures. GABA-B 
receptors are its target. Moreover, it is quietly safe. In a prospective, double-blind, 
placebo-controlled, crossover study, conducted on multiple sclerosis patients, a 
statistically significant reduction of spasticity was shown in gabapentin-treated 
patients compared to placebo [40]. The most efficient and safe dose range is still an 
open question. A dose range between 2700 and 3600 mg/day, as therapy for spastic-
ity due to upper motor neuron syndrome, was found as efficient and safe. However, 
doses of 400 mg orally three times a day, in another double-blind, placebo-
controlled crossover study, were shown to be effective in the treatment of spasticity 
and muscle painful cramps in patients with MS [41]. Nevertheless, considering the 
magnitude of the effect and the good tolerability of the drug, the evidence is on a 
weak recommendation for using gabapentin to reduce spasticity in MS [42].
2.3.3 Oral baclofen
Baclofen is another common drug diffusely used in spasticity. This drug is a 
GABA-B receptor agonist. Its physiological effect is a suppression of excitatory 
neurotransmitter release and, as a consequence, a potentiation of presynaptic 
inhibition. The main clinical effects are related mainly to the reduction in flexor-
extensor spasms and mono- and polysynaptic reflexes. Obviously, related to its 
mechanism of action, this drug may induce dose-dependent side effects, quite 
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similar to those seen with diazepam [43], although less frequent and less severe. 
However, sedation, confusion, dizziness, drowsiness, fatigue, and ataxia have been 
described as the common side effects observed in baclofen studies. Spasticity due 
to spinal cord lesions is the main indication to treat with baclofen. Unfortunately, 
in literature, there are very little studies focused on functional changes, so as a 
consequence, there is no evidence for effectiveness on functional activities such as 
gait, ambulation, or daily living activities. Moreover, also for oral baclofen, a weak 
recommendation for treatment of spasticity in MS has been shown [42]. It’s notable 
that there is no evidence of significant differences between diazepam, tizanidine, 
and oral baclofen, regarding therapeutic effects on spasticity [43, 44].
2.3.4 Tizanidine
Tizanidine, an imidazole derivative approved for the treatment of patients with 
spasticity [45], acts as an alpha-2 agonist, both in the spinal and supraspinal level. 
Presynaptic activity reduction of the excitatory interneurons represents the main 
physiological effect of this treatment. The coeruleo-spinal pathway, because of its 
involvement in the control of spinal cord activities, was shown as the main target 
in order to induce clinical effect during tizanidine treatment [46]. Consequently, 
reduction in tonic and stretch polysynaptic reflexes can be observed. Because 
of co-contraction reduction, which is observed, a possible effect on reciprocal 
inhibition is questionable. Possible side effects include sedation, dizziness, and 
dry mouth. Nevertheless, with respect to diazepam or baclofen, weakness is not 
reported as a great problem [47]. From the literature, the indications for its use 
are mainly in spasticity due to spinal cord lesions [48]. It has been particularly 
used in multiple sclerosis patients [49]. In spasticity caused by cerebral lesions, its 
efficacy is less well documented in literature. However, there are a certain number 
of reports regarding its antispastic efficacy, also in controlled studies vs. placebo. 
In the treatment of spasticity due to cerebral lesions, there are some evidences of its 
greater efficacy than diazepam [47]. However, there is very little information about 
the possible functional changes resulting from this treatment, i.e. quality of life and 
self-care. In fact, although it has been shown to have an antispastic effect, we do not 
know whether this will translate into long-term functional benefit for the patients. 
In clinical practice, tizanidine is usually well-tolerated. Drowsiness and dry mouth 
are the most common although are rare side effects. A range of 24–36 mg is nor-
mally the therapeutic dose (20% mean reduction in muscle tone), usually divided 
in three daily doses [50]. Like oral baclofen and diazepam, there is a consensus for a 
weak recommendation for the use of tizanidine [42].
2.3.5 Dantrolene
Among the oral dugs, dantrolene is the only one which acts outside the central 
nervous system [51]. It acts on the inhibition of calcium release from the sarco-
plasmic reticulum, so, as a final effect, it reduces in muscle the excitation-coupling 
reaction between actin and myosin fibres. The documented clinical effects are a 
reduction of muscle tone and phasic reflexes, reduction of spasm, and an increased 
range of passive motion. Unfortunately, a frequent occurrence of side effects is 
described with this drug, such as gastrointestinal symptoms, weakness, and seda-
tion although this is less than that seen with other treatments. Over all, a serious 
side effect with the use of dantrolene is hepatotoxicity, which occurs frequently 
[51]. In patients with spasticity due to cerebral lesions, dantrolene is the only drug 
with evidence of efficacy, so from a pure clinical point of view, this is very disap-
pointing. In fact, dantrolene in approved in patients with stroke, cerebral palsy, 
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traumatic brain injuries, and spinal cord lesions. As shown for baclofen, also for 
dantrolene, there are many evidences of efficacy and safety of its antispastic effect 
proven vs. placebo, but no studies focused on functional changes in activities of 
daily living. It’s notable that dantrolene is also used to prevent muscle stiffness and 
spasms caused by malignant hyperthermia (a rapid rise in body temperature and 
severe muscle contractions) that can occur during surgery with certain types of 
anaesthesia [52].
2.3.6 Cannabinoids
It is known, from many evidences, that the psychoactive ingredient in cannabis, 
delta-9-tetrahydrocannabinol (delta-9-THC), is able to treat muscle spasticity and 
pain. Two types of cannabinoid receptors can be described: CB1 and CB2. CB1s 
are located both in the central and peripheral neurons. CB1 and CB2 receptors are 
equally activated by delta-9-THC, a cannabinoid receptor agonist [53, 54]. On the 
contrary, cannabidiol, a natural cannabinoid, is inactive on the CB1 receptor. Some 
studies reported that cannabis extracts, containing approximately equal concentra-
tions of delta-9-THC and cannabidiol administered through sublingual way, can 
significantly reduce spasticity. During the last years, several studies investigated 
and argued on the efficacy and safety of oral cannabinoid administration in 
MS patients as an add-on treatment for spasticity. A multicentre, double-blind, 
placebo-controlled trial showed that in MS spasticity treatment, cannabinoid may 
help to treat MS-related spasticity and pain [53]. However, according to the results 
from clinical trials, it is not allowed to use cannabinoids in MS as a general use. In a 
recent study, 630 MS patients affected by muscle spasticity were randomised to be 
treated with oral delta-9-THC, cannabis extract, or placebo for up to 12 months. The 
results showed a controversial effect; in fact, there was a small treatment effect on 
muscle spasticity and disability as functional independence measure, but patients’ 
sensation was that these drugs were helpful in treating their disease [54]. Adverse 
side effects are generally mild, in particular dry mouth, somnolence, dizziness, 
nausea, and rarely intoxication. However, there is a need of longer-term studies 
to evaluate other, well-known, adverse side effects of cannabinoid such as risks of 
lung cancer and other respiratory dysfunctions. A recent multicentre observational 
study confirmed the efficacy and safety of delta-9-THC in clinical practice, as an 
effective and safe option for patients with MS with moderate to severe spasticity 
resistant to common antispastic drugs [55]. In a recent consensus, a significant 
recommendation for the use of cannabinoids in spasticity emerged, particularly for 
oromucosal spray nabiximols, as treatment of spasticity in MS; the strength of the 
recommendation is strong [42].
2.4 Botulinum toxin
BTX type A is considered as the first-line treatment of multifocal muscle 
overactivity, thanks to its better efficacy and safety profile with respect to systemic 
approach with drugs. Different from baclofen or tizanidine, the efficacy of BTX 
type A has been demonstrated in self-care improvement (in particular for wash-
ing and dressing) and in active movements for the leg, with gait improvement if 
possible. Except for using kinematic analysis, no improvement was possibly shown 
in active movement or function in the upper limb. Pain was also reduced by BTX 
treatment as demonstrated in literature. Four forms of BTX are currently avail-
able in Europe: three type As (BOTOX®, Allergan; Dysport®, Ipsen-Pharma; 
Xeomin®, Merz) and one type B (Neurobloc®, Elan-Pharma). It is absolutely rec-
ommended to keep in mind that the units of these four toxins are different, being 
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specific for each one. Injection sites are better detected, using electrical stimula-
tion, as anatomical markers alone may induce to an inaccurate target. The use of 
ultrasound guidance, particularly in children, in identifying muscle site injection, 
is an interesting study object; however, this technique has not been evaluated with 
respect to electrical stimulation guidance for its efficiency. Generally, there are 
no immediate postinjection complications (except for a little pain as a side effect 
related to injection itself). Above all, during the first 3 weeks after each injection 
treatment, there would be a low risk of adverse events (swallowing disorders and 
botulism-like syndrome), so patients and caregivers must be warned as well as 
encouraged to eventually consult if necessary. The effects of treatment could be 
assessed 1–6 weeks after the injection, based on personalised goals decided before 
treatment. The effect of the toxin is not permanent, so repeated injections are often 
needed; nevertheless, a long-lasting effect is also observed. No repeated treatment 
is recommended without a specific assessment. When and if needed according to 
functional evaluation, a minimum delay of 2–3 months between injections must be 
respected, in order to reduce the risk of an immunologic reaction that may induce a 
permanent inefficacy of subsequent treatments. Each subsequent treatment should 
be planned after an accurate functional evaluation according to the pre-therapeutic 
identified goals and task, as well as tolerance. So, a review of the dose and treated 
muscles could be scheduled. If therapeutic effects continue to be evident, repeated 
injections can be planned [33, 56–60]. Physical therapy has to be considered after 
BOTOX injections. Regarding maximum doses, according to European Consensus, 
it should be considered:
• Per session: 1500 MU Dysport® 600 U BOTOX®.
• Per site: 125 MU Dysport® 50 U BOTOX®.
It is notable that these dosages are identified relatively to acceptable side effects, 
in order to be safe. Moreover, each product could be effective with different doses 
for each patient, in terms of both efficacy and safety [61]. As well as the cannabi-
noid, there is a strong recommendation of the use of BTX to reduce muscle tone in 
spasticity do to multiple sclerosis [42].
2.5 Alcohol and phenol
Localised and loco-regional spasticity may effectively be treated by selective 
neurolysis. Coagulation and denaturing of proteins induced by phenol perineu-
rally injected lead to cellular and axonal damage. Unfortunately, this chemical 
denervation is irreversible; moreover, the effects of phenol are not selective 
because also vascular and sensory structures can be destroyed [62]. In fact, the 
main recommendation choosing this approach is to identify preferably the nerves 
to be treated with a low sensory activity and a high motor predominance (i.e. 
obturator or musculocutaneous nerves, etc.). However, this focal treatment is usu-
ally not used as a first-line therapy, except in the case of particularly problematic 
overactivity affecting a big area under a single motor nerve control, for example, 
musculocutaneous nerve for biceps brachii muscle or obturator nerve for thigh 
adductor muscles. This may allow to use in the same patient BTX to treat other 
muscles, without the risk of an overdose. Electrical stimulation is used to identify 
a nerve, in order to perform injection on it. Firstly, a transient motor block may 
be a plan, in order to evaluate if chemical neurolysis might be significantly effec-
tive and safe. In fact, the efficacy and/or advantages eventually deriving from 
alcohol or phenol treatment could be evaluated before, in particular with respect 
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to surgery (above all, tissue fibrosis induced by alcohol or phenol, which may 
hamper surgery approach). Advantages are the low cost and the long duration of 
effect. In clinical practice, 5–7% concentrations of phenol in aqueous solution are 
administered.
2.6 Intrathecal baclofen
Intrathecal baclofen (ITB) is a long-term treatment with continuous, intra-
spinal administration via an implanted pump that reduces spasticity, especially in 
spinal injury patients and in multiple sclerosis [63, 64]. For this reason, ITB has 
become the first choice in intractable generalised spasticity, especially when oral 
administration fails to be effective. ITB efficacy in reducing spasticity was dem-
onstrated by several studies [65]. Through direct infusion into the cerebrospinal 
fluid, the baclofen can be concentrated regionally, avoiding liver metabolism, so it 
is totally available for its therapeutic effects. In fact, with respect to oral baclofen 
administration, the ITB, bypassing the blood–brain barrier entirely, needs much 
lower dose in order to obtain the same CSF concentrations; it has been determined 
that the ITB dose is 100–1000 times smaller than the oral daily dose. Depending 
on the pump model, it is possible to modify infusion rate, according to the patient’s 
needs. In several studies ITB was shown as safe and effective in reducing spasticity. 
The complication rate was found to be low, and the efficacy was maintained over 
time [64]. A reduction in the Ashworth scale from 3 to 4 to 1 after ITB implanta-
tion was reported in several studies. Also spasm frequency significantly decreased. 
Some activities of daily living, in particular the ability to sit in a wheelchair and 
nursing care, improved after ITB implant. In some cases, authors showed that 
patients with less severe disability experienced an improvement in the ability to 
transfer, thanks to ITB effect [66]. Side effects, such as vertigo, nausea, nystagmus, 
dysmetria, mouth dryness, headache, amnesia, bladder, and sexual dysfunction, 
have been described in about 4% of patients and mainly are not life-threatening. As 
a red flag, it is notable that concerning gastrointestinal function, ITB could affect 
peristalsis, which could be severely slowed down to paralytic ileus. Nevertheless, 
constipation has previously been reported as an infrequent ITB-induced adverse 
effect, ranging from 3 to 10% of treated patients [67], rarely leading to death 
[68]. Therefore, recognition of constipation in patients treated with ITB is very 
important, not only because constipation is a possible side effect, being reported in 
some study, but also because it may be also a life-threatening complication. ITB has 
been used in patients with leg diffuse muscle overactivity. This type of treatment 
should be used above all in patients, in which muscle overactivity impaired posture, 
nursing, and personal independence or causes pain [63]. Several assessments are 
required before planning a definite pump implantation, performing drug test 
injection via lumbar puncture or via a temporary access device. Efficacy may be 
evaluated during the following 3–4 h. The first test dose is usually recommended 
up to 50 μg in adults, picking up gradually to a maximum dose of 150 μg, eventually 
reached after 3 days. A risk of overdose should be always evaluated, in particular 
regarding the effects on consciousness level and respiratory disorders. So, a spe-
cialised medical team is needed in order to monitor patient after and during the 
4 h following the test. Only after the end of this test, if the treatment has been 
well-tolerated and effective, the team may make the decision to implant the pump. 
It is important to monitor the patient during the entire follow-up period, in order to 
prevent and/or detect collateral effects related to the procedure (displacement and/
or obstruction of the catheter, infection, etc.), which may induce a serious with-
drawal syndrome. ITB is often recommended for the treatment of spasticity, with a 
strong evidence of efficacy [42].
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2.7 Surgery
Surgery may play an important role in the treatment of chronic muscle overac-
tivity or for the after-effects induced by spasticity that become functional impair-
ments (e.g. irreducible equinovarus foot), but it is not the first-line treatment. 
Because of its potential adverse events and its definite effects, surgical techniques 
should be reserved only in selected patients in order to reach different goals: 
hygiene, standing, transferring, walking, and the use of assistive devices. It involves 
neurosurgery and orthopaedic surgery. Surgical procedures may include one or 
more of the techniques described below. Peripheral neurotomy may include partial 
or segmental resection of a motor nerve, involving spastic muscles. In order to bal-
ance agonists and antagonists overlapping the muscle activity, a selective peripheral 
neurotomy is recommended to maintain a “functional” muscle tone. Collateral 
branches of the posterior tibial nerves and obturator nerves are commonly the 
main targets for the legs (e.g. ankle clonus, equinus, inversion of the foot). For 
the arms, neurotomy of the musculocutaneous, median, and ulnar nerves showed 
good results regarding efficacy and safety [69]. Other surgery techniques, such as 
rhizotomies, although used, have potential collateral effects and complications [70]. 
Musculoskeletal surgery, performed on the muscle or the tendon itself, aims to treat 
spasticity consequences, such as contracture and joint deformities. Tendon transfers 
(e.g. tibialis anterior) and lengthening are conservative treatments commonly pro-
posed [69]. Tenotomy may be considered in the case of muscle contracture without 
active functional objectives [69]. Hip displacements and foot deformities induced 
by severe spasticity may be sometimes treated with osteotomies [69]. Arthrodesis 
may be the only solution to stabilise joints, notably ankle and foot joints in case of 
severe paresis associated with strong muscle overactivity and hypoesthesia [69].
3. Treatment options of dystonia
3.1 Indications of treatment
Treatment options of the management of dystonia include pharmacological 
therapies, injections, and surgical interventions. The main pharmacological thera-
pies are anticholinergics (particularly trihexyphenidyl), baclofen, benzodiazepines 
(particularly clonazepam), and dopamine-related medications. However, medical 
therapy in dystonia is largely empiric and at times may seem anecdotal. Three main 
neurotransmitter systems are involved: cholinergic generally acting as antagonist 
at postsynaptic M1 receptor, GABAergic-like baclofen, and dopaminergic systems. 
Dopaminergic treatments can be divided into two: levodopa and dopamine reduc-
ing medications like presynaptic dopamine depleters such as tetrabenazine and 
postsynaptic dopamine-blocking agents, such as clozapine or neuroleptics. The 
therapeutic strategy, carried out by Fahn [71], is to “start low and go slow”: medica-
tions should be started at a low dose and upped slowly to the lowest effective dose, 
in order to reduce symptoms without side effects. The rate of titration may depend 
on age: every 3–4 days in children, compared to every 1 week in adults. A combina-
tion approach is used when monotherapy achieves a “good” dose, but symptom 
control is incomplete. The question is which medications should be started first?
3.2 Cholinergic system agents
In 1952, beneficial effects of trihexyphenidyl in writer’s cramp and “dystonia 
musculorum deformans” were first reported [72, 73]. The first open-label study of 
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high-dose anticholinergics in dystonia using trihexyphenidyl and ethopropazine 
was conducted by Fahn [71]. Various forms of dystonia, both “primary and second-
ary,” can be treated with anticholinergics, except for tardive dystonia and Meige 
syndrome. Studies showed a good effect in 61% of the children and 38% of the 
adults, with mean trihexyphenidyl doses of 41 and 24 mg, respectively. More ben-
efit was demonstrated in children, possibly due to better tolerability, and in patients 
who received treatment earlier, within 5 years of disease onset [74]. Several studies 
have demonstrated that anticholinergic drugs may be useful to treat various forms 
of dystonia including focal [75], cranial [76], and secondary dystonia including 
dystonia in cerebral palsy [74], after ischemic stroke [77], and in tardive dystonia 
[78]. Side effects can be divided into central ones, which include sedation, cognitive 
slowing, confusion, memory impairment, psychosis and chorea, and autonomic 
side effects, which include blurred vision, due to mydriasis, dry mouth, urinary 
retention, and constipation.
3.3 GABAergic system agents
Baclofen was reported to be useful in tardive dystonia [79]. Just in 1988, Greene 
published a retrospective open-label study, showing that 20% of 108 patients 
had benefits from baclofen at a mean daily dose of 82 mg [80]. Later, Greene and 
Fahn also reported beneficial effects of baclofen in 7 of 16 patients with idiopathic 
childhood dystonia [81]. ITB was tried initially for spasticity and later in dystonia 
[82]. In 1991 Narayan and colleagues showed the efficacy of ITB in axial dystonia 
not responding to other drugs [83] and subsequently in dystonic cerebral palsy with 
lower extremity involvement [84]. Albright reported the use of intraventricular 
baclofen in two patients with dystonic cerebral palsy, one of whom previously failed 
ITB therapy and the other has a complex spinal anatomy precluding the intrathe-
cal procedure [85]. Nevertheless, baclofen is generally considered as a second-line 
agent, due to its significant side effects like drowsiness, dizziness, fatigue, and 
nausea. Regarding benzodiazepines, diazepam therapy was described in “dystonia 
musculorum deformans progressiva” and spasmodic torticollis [86]. In 1988, the 
benefit of clonazepam was shown by Greene in 16% of 115 patients with dystonia, 
also including secondary dystonia [80]. Also in acquired hemidystonia, as shown 
in a report of 33 patients, clonazepam and diazepam were found to be the most 
effective drugs. Clonazepam and diazepam are the two most commonly used drugs, 
partly due to their relatively long half-lives. The side effects of benzodiazepines 
include sedation, depression, nocturnal drooling, and behavioural disinhibition. 
Benzodiazepines are considered a second- or third-line agent.
3.4 Dopaminergic system agents
In 1976 Segawa firstly used levodopa as a treatment in dystonia, showing a 
dramatic response to low-dose levodopa in two patients affected by “hereditary pro-
gressive dystonia with marked diurnal fluctuations” [87], later named Segawa syn-
drome. In dystonia therapy, levodopa is used (1) as an aetiology-specific treatment 
in dopa responder dystonia and (2) as a symptomatic therapy in other forms of 
dystonia where the dramatic response to levodopa is unfortunately not replicated. 
Levodopa may also be used to treat dystonia symptoms which may complicate a 
parkinsonian syndrome [88]. In clinical practice, levodopa or dopamine agonists are 
rarely used to treat dystonia symptomatically. The side effects of levodopa include 
nausea, orthostatic hypotension, and psychosis. In 1972, Swash reported only a 
slight benefit of tetrabenazine in spasmodic torticollis [89]. In 1982, a double-blind 
crossover trial by Jankovic demonstrated an improvement in 11 of 12 patients [90]. 
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Tetrabenazine has been used in various forms of dystonia; however, benefits are 
greater in tardive dystonia than that of the other forms [91]. Tetrabenazine is rarely 
used as a first-line agent, except in tardive dystonia [92].
4. Conclusions
Spasticity and dystonia syndromes and their consequences negatively impact 
the quality of life of patients, so management of symptoms represents an important 
care issue. The best choice of antispastic treatments depends not only on the level of 
spasticity but also on the outcome achievable, according to a task-oriented reha-
bilitation programme. In this respect, it is important to underline the importance 
of the individualised rehabilitative project, which can be carried out only through 
a multidisciplinary approach, in which all available options must be targeted to the 
real needs of the patients, keeping into account that the final goal is the reduction 
of disability and improvement of the quality of life. With advances in diagnosis and 
treatment, therapeutic strategies for the management of spasticity and dystonia 
symptoms, including pharmacological treatments, have evolved. Progresses in other 
areas such as BTX, neuromodulation, and disease-specific treatment have changed 
the way patients are treated. Nevertheless, dystonia remains a challenging field in 
both diagnostic and therapeutic aspects. Further understanding of its pathophysi-
ology may shed light on more specific therapies. In conclusion, the management 
of spasticity and dystonia may include a proper diagnosis and classification with 
an evaluation of the aetiology underlying the pathological features and a clini-
cal assessment of the functional impairment. For both conditions, therapeutic 
approaches, usually limited to symptomatic therapy, must then be tailored to the 
individual needs of the patient.
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